JingAo Solar v Chint New Energy (CFI, 28 November 2025)
| Date | 28 November 2025 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Local Division |
| Type of action | Counterclaim for infringement |
| Case number(s) | UPC_CFI_425/2025;UPC_CFI_751/2024 |
| Registry reference | UPC_CFI_425/2025and · UPC_CFI_751/2024 |
| Parties | JingAo Solar Co., Ltd. v. Chint New Energy Technology Co. a.o. |
Official decision (PDF) · UPC registry entry
Case timeline
- 25 June 2026 : Natural person v SWARCO Futurit Verkehrssignalsysteme (CFI, 25 June 2026) UPC_CFI_425/2025
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In a decision of 28 November 2025, made in proceedings UPC_CFI_425/2024 and UPC_CFI_751/2024, the Munich Local Division held EP 2 787 541 (solar cell with a tunnelling layer, TOPCon technology) valid and infringed by the Chint/Astronergy group’s ASTRO N modules in Germany, France, Italy and the Netherlands. The counterclaim for revocation was dismissed in its entirety.
The decision is of interest for its handling of inventive step attacks: several prior art combinations were excluded as late-filed under Rule 263, and the competition law defence failed for want of reliable market data.
Facts and procedure
The patent, filed by LG Electronics in 2014 and granted in 2022, was assigned to Jinko and then to the claimant. EPO opposition proceedings ended with the patent maintained with an amended claim 13, an appeal is pending. JingAo Solar sued six group companies, which counterclaimed for revocation. An order of 19 March 2025 held that the competition law allegations were not substantiated, and an order of 31 March 2025 allowed the amendment of the claims and of the infringement action. The oral hearing took place on 28 October 2025.
The applicable law
Validity was assessed under Art. 54, 56, 123(2) and 138(1)(c) EPC. Inventive step followed the problem and solution approach as framed by the Court of Appeal in its decisions of 25 November 2025 (Amgen v Sanofi, Edwards v Meril). The ancillary remedies rest on Art. 63 and 69 UPCA and Rules 118 and 354.
Question
Does the patent survive the added matter, sufficiency, novelty and inventive step attacks, and do the defendants’ TOPCon modules fall within claim 1?
Decision
On construction, pinholes do not prevent the tunnelling layer from being « entirely formed », and « directly connected » excludes any intermediate material between electrode and doped area (section IV). Neither added matter nor insufficiency was found (sections V.1 and V.2). Claim 1 is novel over D20, whose « transition region » lies within the substrate (section V.3).
On inventive step (section V.4), the combinations D28 with D33, D28 with D31, D8 alone, D8 with common general knowledge and D6 with D28 were not admitted as late-filed, D33 having been known to the defendants. The other attacks failed: D22 teaches away from the claimed position of the tunnelling layer, no motivation was shown for D25, and the skilled person starting from D7 would not consult D26, a back-junction cell.
Infringement was established from the defendants’ own white paper and test reports (section VII). The « de facto standard » defence was rejected, the market share relied on being only a forecast (section VIII), and the proportionality objection, a blanket assertion, failed (section IX). The order grants an injunction with penalties of up to EUR 20,000 per product, information from 31 August 2022, recall and destruction, damages and interim costs of EUR 124,000. Publication, a grace period, security of EUR 10 million and confidentiality were refused.
Key points for practice
- The division excluded late-filed prior art combinations under Rule 263, including where the document was already known to the party relying on it (section V.4).
- A defence under Art. 102 TFEU requires actual market data. A market share forecast is not enough (section VIII).
- A proportionality objection under Art. 63(1) UPCA needs concrete argument (section IX).
- Practical point: every prior art combination should be pleaded at the counterclaim stage, or it may not be examined at all.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 63, 65(5) and 69(1)
- Rules of Procedure
- Rules 13.1, 118, 263 and 354
- European Patent Convention
- Art. 54, 56, 123 and 138
- Case law cited
- Amgen v Sanofi-Aventis Deutschland, Court of Appeal, 25 November 2025, Meril v Edwards, Court of Appeal, 25 November 2025, Abbott Diabetes Care v Sibio, Court of Appeal, 14 February 2025
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Patent infringement action.
Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantJingAo Solar Co., Ltd.3 decisions in the corpusFollow this party
- defendantChint New Energy Technology Co. a.oFollow this party
Decisions in the same proceedings and documented appeals
- 28 November 2025 JingAo Solar v Chint New Energy (CFI, 28 November 2025) Counterclaim for infringement · UPC_CFI_425/2025, UPC_CFI_751/2024
- 25 June 2026 Natural person v SWARCO Futurit Verkehrssignalsysteme (CFI, 25 June 2026) Revocation Action · UPC_CFI_425/2025
Lorsque l’OEB limite le brevet pendant l’action en nullité, la JUB apprécie la validité de la version limitée, l’article 105 bis, paragraphe 2, de la CBE étant sans incidence. Tous les moyens de nullité sont écartés, l’action est rejetée et le brevet maintenu tel que limité.
What the record states
- Nature of the act
- Counterclaim for infringement
- Outcome (Dhenne Avocats summary)
- Le brevet est jugé valable et contrefait par les modules ASTRO N dans quatre États. La demande reconventionnelle en nullité est rejetée et l'interdiction, le rappel, la destruction et la réparation sont ordonnés.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 787 541mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Natural person v SWARCO Futurit Verkehrssignalsysteme (CFI, 25 June 2026) cited in this record
- Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) cited in this record
- Meril Italy v Edwards Lifesciences (CoA, 25 November 2025) cited in this record
- JingAo Solar v Chint New Energy Technology (CFI, 31 March 2025) cited in this record
- Chint New Energy Technology v JingAo Solar (CFI, 19 March 2025) cited in this record
- Abbott Diabetes Care v Sibio (CoA, 14 February 2025) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 787 541 | Mentioned in the analysis (role not qualified) Also mentioned in 4 other decision(s): Chint New Energy v JingAo Solar (CoA, 9 July 2025) · Chint New Energy v JingAo Solar (CoA, 20 May 2025) · JingAo Solar v Chint New Energy Technology (CFI, 31 March 2025) · Chint New Energy Technology v JingAo Solar (CFI, 19 March 2025) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.